Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM

Neuro-Oncology

Volumn 13, Issue 4, 2011, Pages 367-375

  Kim, Yong Wan ^a   Liu, Ta Jen ^a   Koul, Dimpy ^a   Tiao, Ningyi ^a   Feroze, Abdullah H ^a   Wang, Jing ^a   Powis, Garth ^a   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Glioma; ShRNA library; Synthetic lethality

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ARTICLE; CELL DEATH; DRUG SENSITIVITY; DRUG TARGETING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC SCREENING; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; RNA SEQUENCE; SIGNAL TRANSDUCTION; VALIDITY;

BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG COMBINATIONS; DRUG DESIGN; DRUG SYNERGISM; GENES, LETHAL; GLIOBLASTOMA; GONANES; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 79955768587     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nor012     Document Type: Article

References (38)

1. Chang SM, Lamborn KR, Kuhn JG, et al. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 2008;10(4):631-642
2. de Groot JF, Gilbert MR. New molecular targets in malignant gliomas Curr Opin Neurol 2007;20(6):712-718. (Pubitemid 350085016)
3. Omuro AM. Exploring multi-targeting strategies for the treatment of gliomas. Curr Opin Investig Drugs 2008;9(12):1287-1295.
4. Cappuzzo F. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 2005;97(12):868-869. (Pubitemid 41417931)
5. Reardon DA, Egorin MI, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol 2005;23(36):9359-9368.
6. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17(11):1717-1734.
7. Yang G, Sun Q, Teng Y, Li F, Weng T, Yang X. PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor lalpha signaling and endoplasmic reticulum stress. Development 2008; 135(21):3587-3597.
8. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM, Fulda S. Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor-and drug-induced apoptosis. Cancer Res 2008;68(15):6271-6280.
9. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol Cancer Ther 2005;4(1):101-112. (Pubitemid 40268071)
10. Iorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007;6(7):556-568. (Pubitemid 47019444)
11. Aza-Blanc P, Cooper CL, Wagner K, Batalov S, Deveraux QL, Cooke MP. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 2003;12(3) 627-637. (Pubitemid 37222485)
12. Mukherji M, Bell R, Supekova L, et al. Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci USA 2006;103(40):14819-14824. (Pubitemid 44527812)
13. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5(9):689-698. (Pubitemid 41486362)
14. Information. NCfB. NCBI RefSeq database. 2005; www.ncbinlm.nih.gov/ refseq/.
15. Ihie NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 2004;3(7):763-772 (Pubitemid 39193758)
16. Koul D, Shen R, Kim YW, et al. Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol 2010;12(6):559-569.
17. Cerrato JA, Khan T, Koul D, et al. Differential activation of the Fas/CD95 pathway by Ad-p53 in human gliomas. Int J Oncol 2004; 24(2):409-417.
18. Liu TJ, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8(8):2204-2210.
19. Curran MA, Nolan GP. Nonprimate lentiviral vectors. Curr Top Microbiol Immunol 2002;261:75-105. (Pubitemid 34259338)
20. Pounds S, Morris SW. Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 2003;19(10):1236-1242. (Pubitemid 36850216)
21. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme Proc Natl Acad Sci USA 2005;102(16):5814-5819. (Pubitemid 40559642)
22. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061-1068.
23. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351(6):533-542
24. Li A, Walling J, Ahn S, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009;69(5) 2091-2099.
25. Serra V, Markman B, Scaltriti M, etal. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008;68(19):8022-8030.
26. She QB, Chandarlapaty S, Ye Q, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008;3(8):3065.
27. Fan QW, Cheng CK, Nicolaides TP, et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007;67(17):7960-7965. (Pubitemid 47395125)
28. Simi L, Pratesi N, Vignoli M, et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008;130(2):247-253.
29. Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118(9):3065-3074.
30. Tucker CL, Fields S. Lethal combinations. Nat Genet 2003;35(3): 204-205. (Pubitemid 37363168)
31. Iglehart JD, Silver DP. Synthetic lethality-a new direction in cancer-drug development. N Engl J Med 2009;361(2):189-191
32. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004;428:431-437. (Pubitemid 38419689)
33. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2008;14(10):2895-2899.
34. Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK Inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14(12):1351-1356.
35. Simons AH, Dafni N, Dotan I, Oron Y, Canaani D. Genetic synthetic lethality screen at the single gene level in cultured human cells Nucleic Acids Res 2001 ;29(20): 100.
36. Moffat J, Sabatini DM. Building mammalian signalling pathways with RNAi screens. Nat Rev Mol Cell Biol 2006;7(3):177-187.
37. Kustikova OS, Wahlers A, Kuhlcke K, et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003;102(12) 3934-3937. (Pubitemid 37486973)
38. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals offtarget gene regulation by RNAi. Nat Biotechnol 2003;21 (6):635-637. (Pubitemid 36638089)